Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PATHWAY: Pocenbrodib alone or with darolutamide in mCRPC
NCT06785636Phase 2Recruiting
- Sponsor
- Pathos AI
- Start
- Feb 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pocenbrodib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Pathos AI. Started Feb 2025; status: recruiting.
02
Drugs
pocenbrodib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06785636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785636.